Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Anti-interferon gamma Monoclonal Antibody NI-0501

Known as: Anti-IFN gamma Monoclonal Antibody NI-0501, Anti-IFNg mAb NI-0501, NI-0501 
A human monoclonal antibody against the cytokine interferon-gamma (IFN-gamma; IFNg), with potential immunomodulating activity. Upon administration… Expand
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.
BACKGROUND Primary hemophagocytic lymphohistiocytosis is a rare syndrome characterized by immune dysregulation and… Expand
Review
2017
Review
2017
How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis?
Opinion statementCentral nervous system (CNS)-hemophagocytic lymphohistiocytosis (HLH) is not a disease in itself, but it is part… Expand
  • figure 1
  • figure 2
2017
2017
IFNɣ Block, Treosulfan Conditioning and αβ T Cell Deplete PBSCT for XIAP-Deficient HLH
The outcomes of hematopoietic stem cell transplantation (HSCT) for refractory hemophagocytic lymphohistiocytosis (HLH) in X… Expand
  • figure 1
2016
2016
A NOVEL TARGETED APPROACH TO THE TREATMENT OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) WITH NI-0501, AN ANTI-INTERFERON GAMMA MONOCLONAL ANTIBODY
 
2016
2016
Anti-interferon gamma monoclonal antibody NI-0501: A new option to render allogeneic HSCT for HLH safer and more effective?
 
2016
2016
First EU PRIME designations
  • E. Schaper
  • Nature Biotechnology
  • 2016
    • Corpus ID: 205269806
The names of the first four drugs to receive PRIME (PRIority MEDicines) status were released in June by the European Medicines… Expand
Highly Cited
2015
Highly Cited
2015
A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2…
Introduction Primary HLH (pHLH) is a rare immune regulatory disorder invariably lethal if untreated. It is driven by pathologic… Expand
2015
2015
Anti interferon-gamma (IFNγ) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis
Background A growing body of evidence, in animals and humans, suggest that IFNg plays a pathogenic role in primary HLH (pHLH) and… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE